Novel uses for risperidone: Focus on depressive, anxiety and behavioral disorders

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1693-1710

  Ravindran, Arun V ^a   Bradbury, Cheryl ^b   McKay, Martha ^b   da Silva, Tricia L ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Anxiety disorders; Atypical antipsychotic; Behavioral disorders; Dopamine; Mood disorders; Risperidone; Serotonin

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CITALOPRAM; CLONIDINE; FLUVOXAMINE; HALOPERIDOL; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; PROMAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ANTICHOLINERGIC SYNDROME; ANXIETY; ANXIETY DISORDER; AUTISM; BEHAVIOR DISORDER; BINDING AFFINITY; BIPOLAR DISORDER; BULIMIA; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DEMENTIA; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EATING DISORDER; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERSALIVATION; INCREASED APPETITE; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POSTTRAUMATIC STRESS DISORDER; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TARDIVE DYSKINESIA; TRICHOTILLOMANIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; RISPERIDONE;

EID: 34548069752     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1693     Document Type: Review

References (143)

1. TANDON R, FLEISCHHACKER WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. (2005) 79(2-3):145-155.
2. LUBLIN H, EBERHARD J, LEVANDER S: Current therapy issues and umet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. (2005) 20(4):183-198.
3. COHEN LJ: Evaluation of new drugs: risperidone. Pharmacotherapy (1994) 14(3):253-265.
4. SHEN WW: A history of antipsychotic drug development. Compr. Psychiatry (1999) 40(6):407-414.
5. BARTZOKIS G, ALTSHULER L: Biological underpinnings of treatment resistance in schizophrenia: a hypothesis. Psychopharmacol. Bull. (2003) 37(4):5-7.
6. FRANKENBURG FR: Choices in antipsychotic therapy in schizophrenia. Harv. Rev. Psychiatry (1999) 6(5):241-249.
7. ADDINGTON D: Risperidone: integrating research and practice. Br. J. Hosp. Med. (1994) 52(5):223-224.
8. MEGENS AAHP, AWOUTERS FHL, SCHOTTE A et al.: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacoology (1994) 114(1):9-23.
9. LOVE RC, NELSON MW: Pharmacology and clinical experience with risperidone. Expert Opin. Pharmacother. (2000) 1(7):1441-1453.
10. 2 receptor blockade inhibits the firing rate of SNR neurons in the rat brian. Prog. Neumpsychopharmacol. Biol. Psychiatry (2000) 24(4):579-593.
11. RAVINDRAN A, SILVERSTONE P, LACROIX D, VAN SCHAICK E, VERMEULEN A, ALEXANDER J: Risperidone does not affect steady-rate pharmacokinetics of divalproex sodium in patients with bipolar disorders. Clin. Pharmacokinet. (2004) 43(11):733-740.
12. GUPTA S, BLACK DW, SMITH DA: Risperidone: review of its pharmacology and therapeutic use in schizophrenia. Ann. Clin. Psychiatry (1994) 6(3):173-180.
13. KEEGAN D: Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can. J. Psychiatry (1994) 39(9):S46-S52.
14. SONG F: Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J. Psychopharmacol. (1997) 11(1):65-71.
15. VOLAVKA J, CZOBOR P, SHEITMAN B et al.: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry (2002) 159(2):255-262.
16. BILLUPS NF (Ed.): American Drug Index 2007 (51st Edition). Lippincott Williams & Wilkins, New York (2006).
17. SWEETMAN S (Ed.): The Complete Drug Reference (35th Edition). Pharmaceutical Press, London (2007).
18. CANADIAN PHARMACISTS ASSOCIATION (Ed.): Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Professionals. Canadian Pharmacists Association, Toronto (2007).
19. PERLIS RH, WELGE JA, VORNIK LA, HIRSCHFELD RM, KECK PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry (2006) 67(4):509-516.
20. RENDELL JM, GIJSMAN HJ, BAUER MS, GOODWIN GM, GEDDES GR: Risperidone alone or in combination for acute mania. Cochrane Database Syst. Rev. (2006) 1:CD004043.
21. FAVA M: New approaches to the treatment of refractory depression. J. Clin. Psychiatry (2000) 61(Suppl. 1):26-32.
22. RAPAPORT MH, GHARABAWI GM, CANUSO CM et al.: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology (2006) 31(11):2505-2513.
23. GHARABAWI G, CANUSO C, PANDINA G et al.: A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int. J. Neuropsychopharmacol. (2006) 9(Suppl. 1):S236.
24. SHARPLEY AL, BHAGWAGAR Z, HAFIZI S, WHALE WR, GIJSMAN HJ, COWEN PJ: Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J. Clin. Psychiatry (2003) 64(2):192-196.
25. HIROSE S, ASHBY CR Jr: An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J. Clin. Psychiatry (2002) 63(8):733-736.
26. BARBEE JG, CONRAD EJ, JAMHOUR NJ: The effectiveness of olanzapine, risperidone, quetipine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J. Clin. Psychiatry (2004) 65(7):975-981.
27. OSTROFF RB, NELSON JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry (1999) 60(4):256-325.
28. O'CONNOR M, SILVER H: Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J. Clin. Psychopharmacol. (1998) 18(1):89-91.
29. TANI K, TAKEI N, KAWAI M et al.: Augmentation of milnacipran by risperidone in treatment for major depression. Int. J. Neuropsychopharmacol. (2004) 7(1):55-58.
30. STOCKMEIER CA, DICARLO JJ, ZHANG Y et al.: Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. (1993) 266(3):1374-1384.
31. 1A receptor agonism. Brain Res. (2002) 956(2):349-357.
32. BLIER P, SZABO ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry (2005) 66(Suppl. 8):30-40.
33. WAKADE CG, MAHADIK SP, WALLER JL et al.: Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. (2002) 69(1):72-79.
34. ROTHSCHILD AJ: Challenges in the treatment of depression with psychotic features. Biol. Psychiatry (2003) 53(8):680-690.
35. MIODOWNIK C, LERNER V: Risperidone in the treatment of psychotic depression. Clin. Neuropharmacol. (2000) 23(6):335-337.
36. MÜLLER-SIECHENEDER F, MÜLLER MJ, HILBERT A, SZEGEDI A, WETZEL H, BENKERT O: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J. Clin. Psychopharrnacol. (1998) 18(2):111-120.
37. GOTO M, YOSHIMURA R, KAKIHARA S et al.: Risperidone in the treatment of psychotic depression. Prog. Neouropsychopharmacol. Biol. Psychiatry (2006) 30(4):701-707.
38. LANE HY, CHANG WH: Risperidone monotherapy for psychotic depression unresponsive to other treatments. J. Clin. Psychiatry (1998) 59(11):624.
39. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Revised 4th Edition, American Psychiatric Association, Washington, DG (2000).
40. ERZEGOVESI S, GUGLIELMO E, SILIPRANDI F, BELLODI L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder. a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. (2005) 15(1):69-74.
41. LI X, MAY RS, TOLBERT LC, JACKSON WT, FLOURNOY JM, BAXTER LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J. Clin. Psychiatry (2005) 66(6):736-743.
42. MCDOUGLE CJ, EPPERSON CN, PELTON GH, WASYLINK S, PRICE LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry (2000) 57(8):794-801.
43. HOLLANDER E, BALDINI ROSSI N, SOOD E, PALLANTI S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. (2003) 6(4):397-401.
44. RAVIZZA L, BARZEGA G, BELLINO S, BOGETTO F, MAINA G: Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull. (1996) 32(4):677-682.
45. PFANNER C, MARAZZITI D, DELL'OSSO L et al.: Risperidone augmentation in refractory obsessive-compulsive disorder. an open-label study. Int. Clin. Psychopharmacol. (2000) 15(5):297-301.
46. STEIN DJ, BOUWER C, HAWKRIDGE S, EMSLEY RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. Clin. Psychiatry (1997) 58(3):119-122.
47. JACOBSEN FM: Risperidone in the treatment of effective illness and obsessive-compulsive disorder. J. Clin. Psychiatry (1995) 56(9):423-429.
48. SAXENA S, WANG D, BYSTRITSKY A, BAXTER LR: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry (1996) 57(7):303-306.
49. KAWAHARA T, UEDA Y, MITSUYAMA Y: A case report of refractory obsessive-compulsive disorder by risperidone augmentation of clomipramine treatment. Psychiatry Clin. Neurosci. (2000) 54:599-601.
50. AGID O, LERER B: Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J. Clin. Psychiatry (1999) 60(1):55-56.
51. MCDOUGLE CJ, FLEISCHMANN RL, EPPERSON CN et al.: Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J. Clin. Psychiatry (1995) 56(11):526-528.
52. SUN TF, LIN PY, WU CK: Risperidone augmentation of specitic serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med. J. (2001) 24(9):587-592.
53. OZAWA H, WASHIZUKA N, KONDO K: A case of aggravated compulsive act after the treatment with risperidone, an atypical antipsychotic drug. Seishin Shinkeigaku Zasshi (1997) 99(9):706-707.
54. ALEVIZOS B, LYKOURAS L, ZERVAS IM, CHRISTODOULOU GN: Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J. Clin. Psychopharmacol. (2002) 22(5):461-467.
55. GANESAN V, KUMAR TC, KHANNA S: Obsessive-compulsive disorder and psychosis. Can. J. Psychiatry (2001) 46(8):750-754.
56. GIAKAS WJ: Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am. J. Psychiatry (1995) 152(7):1097-1098.
57. KONTAXAKIS V, DIKEOS D, ESCHENBERCHER E, CHRISTODOULOU GN: Successful treatment of obsessive-compulsive disorder with concurrent schizotypal personality disorder. Eur. Neuropsychopharmacol. (1998) 8(Suppl. 1):S28.
58. ANDRADE C: Risperidone may worsen fluoxetine-treated OCD. J. Clin. Psychiatry (1998) 59(5):255-256.
59. RAMASUBBU R, RAVINDRAN AV, LAPIERE YD: Serotonin and dopamine antagonism in obsessive-compulsive disorder, effect of atypical antipsychotic drugs. Pharmacopsychiatry (2000) 33(6):236-238.
60. BLIER P, DE MONTIGNY C: Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology (1999) 21(Suppl. 2):S91-S98.
61. 2 receptors in the rate orbito-frontal cortex: an in vivo electrophysiological study. Psychopharmacology (Berl.) (1999) 143:89-96.
62. EPPERSON CN, FASULA D, WASYLINK S, PRICE LH, MCDOUGLE CJ: Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. J. Child Adolesc. Psychopharmacol. (1999) 9(1):43-49.
63. GABRIEL A: A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can. J. Psychiatry (2001) 46(3):285-286.
64. GINSBERG D: Risperidone monotherapy for treatment-resistant trichotillomania. Prim. Psychiatry (2003) 10(4): 12-21.
65. SENTURK V, TANRIVERDI N: Resistant trichotillomania and risperidone. Psychosomatics (2002) 43(5):429-430.
66. SCAHILL L, TANNER C, DURE L: The epidemiology of tics and Tourette syndrome in children and adolescents. Adv. Neurol. (2001) 85:261-271.
67. ZINNER SH: Tourette disorder. Pediatr. Rev. (2000) 21(11):372-383.
68. BAGHERI MM, KERBESHIAN J, BURD L: Recognition and management of Tourette's syndrome and tic disorders. Am. Fam. Physician (1999) 59(8):2265-2274.
69. BRUGGEMAN R, VAN DER LINDEN C, BUITELAAR JK, GERICKE GS, HAWKRIDGE SM, TEMLETT JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry (2001) 62(1):50-56.
70. GILBERT DL, BATTERSON JR, SETHURAMAN G, SALLEE FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(2):206-214.
71. DION Y, ANNABLE L, SANDOR P, CHOUINARD G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. (2002) 22(1):31-39.
72. SCAHILL L, LECKMAN JF, SCHULTZ RT, KATSOVICH L, PETERSON BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology (2003) 60(7):1130-1135.
73. GAFFNEY GR, PERRY PJ, LUND BC, BEVER-STILLE KA, ARNDT S, KUPERMAN S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(3):330-336.
74. KIM BN, LEE CB, HWANG JW, SHIN MS, CHO SC: Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J. Child Adolesc. Psychopharmacol. (2005) 15(2):318-324.
75. LOMBROSO PJ, SCAHILL L, KING RA et al.: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34(9):1147-1152.
76. BRUUN RD, BUDMAN CL: Risperidone as a treatment for Tourette's syndrome. J. Clin. Psychiatry (1996) 57(1):29-31.
77. MARGOLESE HC, ANNABLE L, DION Y: Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J. Clin. Psychiatry (2002) 63(11):1040-1044.
78. WONG DF, YOUNG LT, PEARLSON GD et al.: D2 dopamine receptors densities measured by PET are elevated in several neuropsychiatric disorders. J. Nucl. Med. (1989) 30(5):731.
79. SINGER HS, WALKUP JT: Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine (Baltimore) (1991) 70(1):15-32.
80. BEATO FL, RODRIQUEZ CT: Antipsychotics in treatment of eating disorders patient: a study with risperidone. Actas Esp. Psiquiatr. (2005) 33(1):33-40.
81. MONTECCHI F, MAGNANI M, MARINUCCI S, GAMBARARA M, DIAMANTI A: Risperidone in the control of negative symptoms in anorexia nervosa in adolescents. Minerva Psichiatr. (1998) 39(4):205-209.
82. CONTE GL, CAMARDESE G, CESARO C: Before and during the treatment of two cases of severe anorexia nervosa: the use of an atypical antipsychotic drug. Psicoterapia e Istituzioni: Review of Psychoanalytical Methodological Research and Clinical Experiences (1999) 6(1-2):187-190.
83. CROCKFORD DN, FISHER G, BARKER P: Risperidone, weight gain, and bulimia nervosa. Can. J. Psychiatry (1997) 42(3):326-327.
84. FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and sutistic disorder in an adolescent girl. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35(7):937-940.
85. FEENEY DJ, KLYKYLO W: Risperidone and tardive dyskinesia. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35(11):1421-1422.
86. NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39(8):941-942.
87. LU ML, SHEN WW: Sleep-related eating disorder induced by risperidone. J. Clin. Psychiatry (2004) 65(2):273-274.
88. HEIDEN A, DE ZWAAN M, FREY R, PRESSLICH O, KASPER S: Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypcal personality disorder. J. Psychiatry Neurosci. (1998) 23(3):179-180.
89. KESSLER RC: US National Comorbidity Study. In: Comorbidity in Affective Disorders. Marcel Dekker, Inc., New York (1999):1-26.
90. BARTZOKIS G, LU PH, TURNER J, MINTZ J, SAUNDRES CS: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol. Psychiatry (2005) 57(5):474-479.
91. REICH DB, WINTERNITZ S, HENNEN J, WATTS T, STANCULESCU C: A preliminary study of risperidone in the treatment of posttraumatic stress disorders related to childhood abuse in women. J. Clin. Psychiatry (2004) 65(12):1601-1606.
92. MONNELLY EP, CIRAULO DA, KNAPP C, KEANE T: Low-dose risperidone as adjunctive therapy for irritable aggression in post-traumatic stress disorder. J. Clin. Psychopharmacol. (2003) 23(2):193-196.
93. HAMNER MB, FALDOWSKI PA, ULMER HG, FRUEH BC, HUBER MG, ARANA GW: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic features. Int. Clin. Psychopharmacol. (2003) 18(1):1-8.
94. PADALA PR, MADISON J, MONNAHAN M et al.: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int. Clin. Psychapharmacol. (2006) 21(5):275-280.
95. DAVID D, FARIA L, MELLMAN TA: Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety (2006) 23(8):489-491.
96. KOZARIC-KOVACIC D, PIVAC N, MUCK-SELER D, ROTHBAUM BO: Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J. Clin. Psychiatry (2005) 66(70):922-927.
97. EIDELMAN I, SEEDAT S, STEIN DJ: Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety (2000) 11(4):187-188.
98. KRASHIN D, OATES EW: Risperidone as an adjunct therapy for post-traumatic stress disorders. Mil. Med. (1999) 164(8):605-606.
99. MONNELLY EP, CIRAULO DA: Risperidone effects on irritable aggression in posttraumatic stress disorder. J. Clin. Psychopharmacol. (1999) 19(4):377-378.
100. LEYBA CM: Risperidone in PTSD. Psychiatr. Serv. (1998) 49(2):245-246.
101. BRAWMAN-MINTZER O, KNAPP RG, NIETERT PJ: Adjunctive risperidone in generalized anxiety disorder. a double-blind, plaeebo-controlled study. J. Clin. Psychiatry (2005) 66(10):1321-1325.
102. PANDINA G, KUJUWA M, CANUSO C, KOSIK-GONZALEZ C, TURKOZ I, GHARABAWI G: Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, placebo-controlled, randomized study. Int. J. Neuropsychopharmacol. (2006) 9(Suppl. 1):S119.
103. SIMON NM, HOGE EA, FISCHMANN D et al.: An open-label trial of risperidone augmentation for refractory anxiety disorders. J. Clin. Psychiatry (2006) 67(3):381-385.
104. GALYNKER I, KHAN A, GREBCHENKO Y et al.: Low-dose risperidone and quetiapine for co-morbid anxiety and depression. J. Clin. Psychiatry (2005) 66(4):544.
105. YATHAM LN, GOLDSTEIN JM, VIETA E et al.: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry (2005) 66(Suppl. 5):40-48.
106. BIEDERMAN J, MICK E, WOZNIAK J, ALEARDI M, SPENCER T, FARAONE SV: An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. (2005) 15(2):311-317.
107. SIMEON J, MILIN R, WALKER S: A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(2):267-275.
108. BARNARD L, YOUNG AH, PEARSON J, GEDDES J, O'BRIEN G: A systematic review of the use of atypical antipsychotics in autism. J. Psychopharmacol. (2002) 16(1):93-101.
109. TROOST PW, LAHUIS BE, STEENHUIS MP et al.: Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(11):1137-1144.
110. MCDOUGLE CJ, SCAHILL L, AMAN MG et al.: Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry (2005) 162(6):1142-1148.
111. SHEA S, TURGAY A, CARROLL et al.: A risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics (2004) 114(5):634-641.
112. MCCRACKEN JT, MCGOUGH J, SHAH B et al.: Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. (2002) 347(5):314-321.
113. PANDINA G, BOSSIE C, YOUSSEF E, ZHU Y, DUNBAR F: Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord. (2007) 37(2):367-373.
114. LUBY J, MRAKOTSKY C, STALETS MM et al.: Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J. Child Adolesc. Psychopharmacol. (2006) 16(5):575-587.
115. TROOST PW, ALTHAUS M, LAHUIS BE, BUITELAAR JK, MINDERAA RB, HOEKSTRA PJ: Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. J. Child Adolesc. Psychopharmacol. (2006) 16(5):561-573.
116. NAGARAJ R, SINGHI P, MALHI P: Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J. Child Neurol. (2006) 21(6):450-455.
117. MALONE RP, MAISLIN G, CHOUDHURY MS, GIFFORD C, DELANEY MA: Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(2):140-147.
118. MASI G, COSENZA A, MUCCI M. BROVEDANI P: Risperidone monotherapy in preschool children with pervasive developmental disorders. J. Child Neurol. (2001) 16(6):395-400.
119. MASI G, COSENZA A, MUCCI M, BROVEDANI P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J. Clin. Psychiatry (2003) 64(9):1039-1047.
120. GUNTHER T, HERPERTZ-DAHLMANN B, JOLLES J, KONRAD K: The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behaviour disorder. J. Child Adolesc. Psychopharmacol. (2006) 16(6):725-735.
121. MARTIN A, SCAHILL L, ANDERSON GM et al.: Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am. J. Psychiatry (2004) 161(6):1125-1127.
122. LINDSAY RL, ARNOLD LE, AMAN MG et al.: Dietary status and impact of risperidone on nutritional balance in children with autism: a Pilot Study. J. Intellect. Dev. Disabil. (2006) 31(4):204-209.
123. LOONEN AJM, LOOS JCM, VAN ZONNEVELD TH: Outcomes and costs of treatment with risperidone in adult and elderly patients: the δ patient using risperidone study. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26(7-8):1313-1318.
124. BEIER MT: Pharmacotherapy for behavioural and psychological symptoms of dementia in the elderly. Am. J. Health Syst. Pharm. (2007) 64(2 Suppl. 1):S9-S17.
125. ANGELINI A, BENDINI C, NEVIANI F, NERI M: Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe? Arch. Gerontol. Geriatr. (2007) 44(Suppl.):35-43.
126. SUH GH, SON HG, JU YS et al.: A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am. J. Geriatr. Psychiatry (2004) 12(5):509-516.
127. DE DEYN PP, RABHERU K, RASMUSSEN A et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology (1999) 53(5):946-955.
128. CHAN W, LAM LC, CHOY CN, LEUNG VP, LI S, CHIU HF: A double-blind randomized comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int. J. Geriatr. Psychiatry (2001) 16(12):1156-1162.
129. GARERI P, COTRONEO A, LACAVA R et al.: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia (BPSD). Arch. Gerotol. Geriatr. (2004) 38(Suppl.):207-215.
130. BRODATY H, AMES D, SNOWDON J et al.: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin. Psychiatry (2003) 64(2):134-143.
131. KATZ I, JESTE DV, MINTZER JE, CLYDE C, NAPOLITANO J, BRECHER M: Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry (1999) 60(2):107-115.
132. DEBERDT WG, DYSKEN MW, RAPPAPORT SA et al.: Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am. J. Geriatr. Psychiatry (2005) 13(8):722-730.
133. SCHNEIDER LS, TARIOT PN, DAGERMAN KS et al.: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's discase. N. Engl. J. Med. (2006) 355(15):1525-1538.
134. MINTZNER J, GREENSPAN A, CAERS I et al.: Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am. J. Geriatr. Psychiatry (2006) 14(3):280-291.
135. KATZ IR, RUPNOW M, KOZMA C, SCHNEIDER L: Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am. J. Geriatr. Psychiatry (2004) 12(5):499-508.
136. ARRIOLA E, IGNACIO DIAGO J, ANTONIO BURON J, GALLEGO R: Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. Am. J. Geriatr. Pharmacother. (2005) 3(1):8-16.
137. ONOR ML, SAINA M, TREVISIOL M, CRISTANTE T, AGUGLIA E: Clinical experience with risperidone in the treatment of behavioural and psychological symptoms of dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31(1):205-209.
138. RABINOWITZ J, KATZ I, DE DEYN PP, BRODATY H, GREENSPAN A, DAVIDSON M: Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J. Clin. Psychiatry (2004) 65(10):1329-1334.
139. DE DEYN PR KATZ IR, BRODATY H, LYONS B, GREENSPAN A, BURNS A: Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin. Neurol. Neurosurg. (2005) 107(6):497-508.
140. HOLLIS J, TOUYZ S, GRAYSON D, FORRESTER L: Antipsychotic medication dispensing and associated odds ratio of death in elderly veterans and war widows, 2001. Aust. NZ J. Psychiatry (2006) 40(11-12):981-986.
141. SCHNEIDER IS, DAGERMAN KS, INSEL P: Risk of death with atypical antipsychotic drug treaunent for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA (2005) 294(15):1934-1943.
142. HAUPT M, CRUZ-JENTOFT A, JESTE D: Mortality in elderly dementia patients treated with risperidone. J. Clin. Psychopharmacol. (2006) 26(6):566-570.
143. GILL SS, ROCHON PA, HERRMANN N et al.: Atypical antipsychotic drugs and risk of ischaemic stroke: population-based retrospective cohort study. BMJ (2005) 330(7489):445-451.